vs

Side-by-side financial comparison of GEN Restaurant Group, Inc. (GENK) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $49.7M, roughly 1.5× GEN Restaurant Group, Inc.). GEN Restaurant Group, Inc. runs the higher net margin — -3.8% vs -121.9%, a 118.1% gap on every dollar of revenue. On growth, Health Catalyst, Inc. posted the faster year-over-year revenue change (-6.2% vs -9.0%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-5.6M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -1.0%).

Gen Korean BBQ is an American chain of all-you-can-eat Korean barbecue restaurants mainly concentrated around the Western U.S. It opened in 2011, and has since grown to 43 locations as of 2024.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

GENK vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.5× larger
HCAT
$74.7M
$49.7M
GENK
Growing faster (revenue YoY)
HCAT
HCAT
+2.8% gap
HCAT
-6.2%
-9.0%
GENK
Higher net margin
GENK
GENK
118.1% more per $
GENK
-3.8%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$15.3M more FCF
HCAT
$9.6M
$-5.6M
GENK
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-1.0%
GENK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GENK
GENK
HCAT
HCAT
Revenue
$49.7M
$74.7M
Net Profit
$-1.9M
$-91.0M
Gross Margin
Operating Margin
-24.5%
-115.3%
Net Margin
-3.8%
-121.9%
Revenue YoY
-9.0%
-6.2%
Net Profit YoY
-821.4%
-340.3%
EPS (diluted)
$-0.37
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GENK
GENK
HCAT
HCAT
Q4 25
$49.7M
$74.7M
Q3 25
$50.4M
$76.3M
Q2 25
$55.0M
$80.7M
Q1 25
$57.3M
$79.4M
Q4 24
$54.7M
$79.6M
Q3 24
$49.1M
$76.4M
Q2 24
$53.9M
$75.9M
Q1 24
$50.8M
$74.7M
Net Profit
GENK
GENK
HCAT
HCAT
Q4 25
$-1.9M
$-91.0M
Q3 25
$-566.0K
$-22.2M
Q2 25
$-261.0K
$-41.0M
Q1 25
$-301.0K
$-23.7M
Q4 24
$-206.0K
$-20.7M
Q3 24
$25.0K
$-14.7M
Q2 24
$277.0K
$-13.5M
Q1 24
$496.0K
$-20.6M
Gross Margin
GENK
GENK
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
GENK
GENK
HCAT
HCAT
Q4 25
-24.5%
-115.3%
Q3 25
-7.4%
-22.9%
Q2 25
-3.4%
-46.0%
Q1 25
-3.8%
-25.4%
Q4 24
-2.4%
-22.0%
Q3 24
0.2%
-17.9%
Q2 24
3.0%
-20.8%
Q1 24
0.2%
-30.5%
Net Margin
GENK
GENK
HCAT
HCAT
Q4 25
-3.8%
-121.9%
Q3 25
-1.1%
-29.1%
Q2 25
-0.5%
-50.8%
Q1 25
-0.5%
-29.9%
Q4 24
-0.4%
-26.0%
Q3 24
0.1%
-19.3%
Q2 24
0.5%
-17.8%
Q1 24
1.0%
-27.6%
EPS (diluted)
GENK
GENK
HCAT
HCAT
Q4 25
$-0.37
$-1.29
Q3 25
$-0.11
$-0.32
Q2 25
$-0.05
$-0.59
Q1 25
$-0.06
$-0.35
Q4 24
$-0.05
$-0.33
Q3 24
$0.01
$-0.24
Q2 24
$0.06
$-0.23
Q1 24
$0.11
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GENK
GENK
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$2.8M
$95.7M
Total DebtLower is stronger
$13.6M
$153.3M
Stockholders' EquityBook value
$26.5M
$245.8M
Total Assets
$259.9M
$502.6M
Debt / EquityLower = less leverage
0.51×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GENK
GENK
HCAT
HCAT
Q4 25
$2.8M
$95.7M
Q3 25
$4.8M
$91.5M
Q2 25
$9.6M
$97.3M
Q1 25
$15.4M
$342.0M
Q4 24
$23.7M
$392.0M
Q3 24
$22.1M
$387.3M
Q2 24
$29.2M
$308.3M
Q1 24
$28.1M
$327.8M
Total Debt
GENK
GENK
HCAT
HCAT
Q4 25
$13.6M
$153.3M
Q3 25
$10.8M
$153.1M
Q2 25
$7.8M
$153.0M
Q1 25
$6.5M
$382.9M
Q4 24
$6.9M
$382.4M
Q3 24
$7.2M
$345.0M
Q2 24
$7.6M
Q1 24
$7.7M
Stockholders' Equity
GENK
GENK
HCAT
HCAT
Q4 25
$26.5M
$245.8M
Q3 25
$38.1M
$331.9M
Q2 25
$41.0M
$347.5M
Q1 25
$42.8M
$376.8M
Q4 24
$44.1M
$365.2M
Q3 24
$46.5M
$355.0M
Q2 24
$45.9M
$357.0M
Q1 24
$40.4M
$357.2M
Total Assets
GENK
GENK
HCAT
HCAT
Q4 25
$259.9M
$502.6M
Q3 25
$245.5M
$587.1M
Q2 25
$246.3M
$616.2M
Q1 25
$232.4M
$891.5M
Q4 24
$240.4M
$858.9M
Q3 24
$225.7M
$813.0M
Q2 24
$218.8M
$691.7M
Q1 24
$214.5M
$695.1M
Debt / Equity
GENK
GENK
HCAT
HCAT
Q4 25
0.51×
0.62×
Q3 25
0.28×
0.46×
Q2 25
0.19×
0.44×
Q1 25
0.15×
1.02×
Q4 24
0.16×
1.05×
Q3 24
0.16×
0.97×
Q2 24
0.17×
Q1 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GENK
GENK
HCAT
HCAT
Operating Cash FlowLast quarter
$-426.0K
$9.9M
Free Cash FlowOCF − Capex
$-5.6M
$9.6M
FCF MarginFCF / Revenue
-11.3%
12.9%
Capex IntensityCapex / Revenue
10.5%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-24.3M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GENK
GENK
HCAT
HCAT
Q4 25
$-426.0K
$9.9M
Q3 25
$-1.6M
$-464.0K
Q2 25
$3.3M
$-9.0M
Q1 25
$2.2M
$280.0K
Q4 24
$7.3M
$-3.5M
Q3 24
$1.4M
$6.2M
Q2 24
$5.6M
$1.6M
Q1 24
$3.5M
$10.3M
Free Cash Flow
GENK
GENK
HCAT
HCAT
Q4 25
$-5.6M
$9.6M
Q3 25
$-7.7M
$-719.0K
Q2 25
$-6.3M
$-9.2M
Q1 25
$-4.7M
$-390.0K
Q4 24
$165.0K
$-3.9M
Q3 24
$-6.8M
$5.5M
Q2 24
$1.2M
$1.3M
Q1 24
$-586.0K
$10.1M
FCF Margin
GENK
GENK
HCAT
HCAT
Q4 25
-11.3%
12.9%
Q3 25
-15.3%
-0.9%
Q2 25
-11.5%
-11.4%
Q1 25
-8.2%
-0.5%
Q4 24
0.3%
-4.9%
Q3 24
-13.9%
7.2%
Q2 24
2.3%
1.7%
Q1 24
-1.2%
13.5%
Capex Intensity
GENK
GENK
HCAT
HCAT
Q4 25
10.5%
0.4%
Q3 25
12.0%
0.3%
Q2 25
17.5%
0.3%
Q1 25
11.9%
0.8%
Q4 24
13.1%
0.5%
Q3 24
16.9%
0.9%
Q2 24
8.0%
0.4%
Q1 24
8.1%
0.3%
Cash Conversion
GENK
GENK
HCAT
HCAT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
57.96×
Q2 24
20.06×
Q1 24
7.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GENK
GENK

Segment breakdown not available.

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons